TUMOR NECROSIS FACTOR Property

storage temp. 

-20°C

Hazard and Precautionary Statements (GHS)

TUMOR NECROSIS FACTOR Chemical Properties,Usage,Production

Synthesis and release

The TNF gene transcription is induced by nuclear factor-κB (NF-κB), c-Jun, activator protein-1 (AP-1), and nuclear factor associated with activated T cells (NFAT). In the case of pathogen exposure, host immune systems detect pathogen-associated molecular patterns (PAMPs) largely through germline-encoded pattern recognition receptors (PRRs), which engage downstream of the NF-κB pathway to induce TNF mRNA. TNF mRNA contains at least three cis-elements, a 2-aminopurine response element (20 APRE), an AU-rich element (ARE), and a constitutive decay element (CDE) in the 30 untranslated region, which is required for its posttranscriptional regulation through the action of protein kinase R (PKR), RNA-binding proteins/miRNAs, and mRNA decay factors, respectively.

Receptors

There are two types of TNF receptors: TNFR1 (also referred to as p55, p60, TNFRSF1A, and CD120a) and TNFR2 (also known as p75, p80, TNFRSF1B, and CD120b). The human TNFR1 gene, TNFRSF1A, and the TNFR2 gene, TNFRSF1B, consist of 10 exons. The two receptors are single-spanning type I transmembrane proteins and consist of four cysteine-rich domains (CRD1 to CRD4, from N-terminus to C-terminus), which are required for ligand-binding, and a transmembrane region. Both receptors form trimers, which are required for TNF binding. TNFR1 but not TNFR2 has a death domain in its cytoplasmic region. Although sTNF binds to both receptors with high affinity, it preferentially binds to TNFR1 (Kd=1.9×10^-11M) compared with TNFR2 (Kd=4.2×10^-10M). On the other hand, tmTNF strongly activates receptor-mediated downstream signaling. The half-life of TNFR1 and TNFR2 is 180min and 10min, respectively. The primary structures of the mouse, rat, human, cow, and pig of TNFR1 and TNFR2 are shown in Figs. 39B.S5 and 30B.S6.

Agonists and Antagonists

Purified recombinant TNF protein, selective TNFR2 antagonists (TNC-scTNFR2 and EHD2-scTNFR2). Antibodies to TNF, antibodies to TNFR1, antibodies to TNFR2, TNFR2-Fc chimeric protein, a selective human TNFR1 inhibitor based on the technology of nanobody, variable new antigen receptor (VNAR) domains against TNF, dominant-negative TNF mutants.

Clinical implications

Five anti-TNF biologics are approved for clinical use by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, juvenile idiopathic arthritis, Crohn’s disease, and ulcerative colitis. Infliximab is a mousehuman chimera monoclonal antibody against TNF. Adalimumab and golimumab are fully humanized monoclonal antibodies against TNF. Etanercept is a soluble TNFR2-Fc chimera. Certolizumab is a PEGylated Fab fragment.

Description

The importance of TNF is highlighted by its discovery in diseases and multiple key biological processes including immune homeostasis, cell proliferation, differentiation, apoptosis, lipid metabolism, and coagulation. TNF was originally found in mouse serum after the intravenous injection of bacterial endotoxin into mice primed with a viable Mycobacterium bovis Bacillus Calmette-Guerin (BCG) strain; it was shown to cause the necrosis of tumors. Human TNF cDNA and its mRNA were identified in 4β-phorbol 12β-myristate 13α-acetate (PMA)-stimulated HL-60, a monocyte-like cell line derived from a promyelocytic leukemia. The biosynthesis of TNF was clarified by the identification of the cell surface precursor transmembrane form and its processing enzyme, TNF-α-converting enzyme (TACE).

Physical properties

Mr. 26,000 (tmTNF), 17,000 (sTNF). pI 5.8 (human sTNF). TNF is soluble in water. TNF is stable in plasma and serum for 8 h at room temperature and for 24 h at 4°C, -20°C, or -70°C.

General Description

The TNFs (Etanercept, Enbrel) are members of a family ofcytokines that are produced primarily in the innate immunesystem by activated mononuclear phagocytes. Etanercept is a dimeric fusion protein consisting of the extracellularligand-binding portion of the human 75-kDa (p75)TNF receptor (TNFR) linked to the Fc portion of human isotypeIgG1. The Fc component of etanercept contains the CH2domain, the CH3 domain, and the hinge region, but not theCH1 domain of IgG1. These regions are responsible for thebiological effects of immunoglobulins. Each etanerceptmolecule binds specifically to two TNF molecules in the synovialfluid of rheumatoid arthritis patients. It is equally efficaciousat blocking TNFα and TNFβ. The drug is indicatedfor reducing signs and symptoms and inhibiting the progressionof structural damage in patients with moderately toseverely active rheumatoid arthritis. Etanercept is also indicatedfor reducing signs and symptoms of moderately toseverely active polyarticular-course juvenile rheumatoidarthritis in patients 4 years of age and older who have had aninadequate response to one or more disease-modifying antirheumaticdrugs (DMARDS). Etanercept is also indicatedfor reducing signs and symptoms of active arthritis in patientswith psoriatic arthritis.

Clinical Use

Mutations in the TNFRSF1A1 gene are associated with autosomal dominant autoinflammatory disorder, called TNF receptor-associated periodic syndrome (TRAPS); this was first described as familial Hibernian fever (FHF). Polymorphisms in TNFRSF1B have also been identified in some patients with familial rheumatoid arthritis, Crohn’s disease, ankylosing spondylitis, ulcerative colitis, and immune-related conditions such as graft versus host disease associated with scleroderma risk. Some polymorphisms of the TNF gene promoter are observed in patients with systemic lupus erythematosus (SLE), rheumatoid arthritis, and ankylosing spondylitis.

Structure and conformation

TNF exists in two forms: a type II transmembrane protein (tmTNF) and a mature soluble protein (sTNF) . The TNF protein is first produced as tmTNF on the cell surface. tmTNF is enzymatically cleaved at its Ala76-Val77 site by TACE and is released as sTNF. sTNF forms a noncovalently bound homotrimer that is at least eight-fold more active than the monomer. The TNF monomer has 10 antiparallel β-sheets and exhibits a “jelly-roll” topology. Individual subunits form the trimer by an edge-to-face interaction of β-sheets. sTNF contains one disulfide bond (Cys69-Cys101), which plays a role in its biological functions.